Last edition
News about "ESMO Congress "
US Approves TRUQAP for PTEN-Deficient Metastatic Prostate Cancer
TRUQAP (capivasertib) has been approved in the US as the first targeted treatment for PTEN-deficient metastatic Hormone-Sensitive Prostate Cancer (mHSPC). The approval is supported by phase 3 CAPItello-281 data showing a 19 percent reduction in the risk of disease progression or death.
ESMO Congress | 15/06/2026 | By News Bureau
Lupin to Present Phase 1 Data on LNP3693 (STING agonist) at ESMO Congress 2025
Lupin will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, scheduled to be held from October 17 to October 21, 2025.
ESMO Congress | 13/10/2025 | By Dineshwori | 318
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy